How to buy Boston Scientific Corporation (BSX) shares in Australia

Learn how to easily invest in Boston Scientific Corporation shares.

Boston Scientific Corporation
+ $0.15 ( + 0.35%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Boston Scientific Corporation (BSX) is a leading medical devices business with stocks listed in the US. It opened the day at US$44.53 after a previous close of US$44.9. During the day the price has varied from a low of USD43.92 to a high of USD44.71. The latest price was USD44.37 (25 minute delay). Boston Scientific Corporation is listed on the NYSE. All prices are listed in US Dollars.

How to buy shares in Boston Scientific Corporation

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Boston Scientific Corporation. Find the share by name or ticker symbol: BSX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Boston Scientific Corporation reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$44.9, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Boston Scientific Corporation, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Boston Scientific Corporation. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Boston Scientific Corporation stock price (NYSE:BSX)

Use our graph to track the performance of BSX stocks over time.

Boston Scientific Corporation shares at a glance

Information last updated 2021-09-17.
Previous closeUS$44.9
Change US$-0.53
Change % -1.1804%
Volume 7,301,324
Information last updated 2021-10-16.
52-week rangeUS$32.99 - US$46.29
50-day moving average US$44.0629
200-day moving average US$43.0724
Target priceUS$51.15
PE ratio 117.6152
Dividend yield N/A (0%)
Earnings per share (TTM) US$0.369

Where to buy Boston Scientific Corporation stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Boston Scientific Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Boston Scientific Corporation share growth calculator


Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Boston Scientific Corporation shares?

Before you consider Boston Scientific Corporation, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Boston Scientific Corporation price performance over time

Historical closes compared with the last close of $44.37

1 week (2021-10-07) 1.72%
1 month (2021-09-17) 44.37
3 months (2021-07-16) 5.39%
6 months (2021-04-16) 8.46%
1 year (2020-10-16) 15.43%
2 years (2019-10-17) 16.24%
3 years (2018-10-17) 16.76%
5 years (2016-10-17) 94.43%

Is Boston Scientific Corporation under- or over-valued?

Valuing Boston Scientific Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Boston Scientific Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Boston Scientific Corporation's P/E ratio

Boston Scientific Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 118x. In other words, Boston Scientific Corporation shares trade at around 118x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Boston Scientific Corporation's PEG ratio

Boston Scientific Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.5389. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Boston Scientific Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Boston Scientific Corporation's EBITDA

Boston Scientific Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$2.9 billion (£2.1 billion).

The EBITDA is a measure of a Boston Scientific Corporation's overall financial performance and is widely used to measure a its profitability.

Boston Scientific Corporation financials

Revenue TTM US$11.2 billion
Operating margin TTM 16.1%
Gross profit TTM US$6.8 billion
Return on assets TTM 3.64%
Return on equity TTM 3.69%
Profit margin 5.2%
Book value 11.213
Market capitalisation US$61.8 billion

TTM: trailing 12 months

Shorting Boston Scientific Corporation shares

There are currently 23.8 million Boston Scientific Corporation shares held short by investors – that's known as Boston Scientific Corporation's "short interest". This figure is 18.9% up from 20.0 million last month.

There are a few different ways that this level of interest in shorting Boston Scientific Corporation shares can be evaluated.

Boston Scientific Corporation's "short interest ratio" (SIR)

Boston Scientific Corporation's "short interest ratio" (SIR) is the quantity of Boston Scientific Corporation shares currently shorted divided by the average quantity of Boston Scientific Corporation shares traded daily (recently around 5.9 million). Boston Scientific Corporation's SIR currently stands at 4. In other words for every 100,000 Boston Scientific Corporation shares traded daily on the market, roughly 4000 shares are currently held short.

However Boston Scientific Corporation's short interest can also be evaluated against the total number of Boston Scientific Corporation shares, or, against the total number of tradable Boston Scientific Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Boston Scientific Corporation's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Boston Scientific Corporation shares in existence, roughly 20 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Boston Scientific Corporation shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Boston Scientific Corporation.

Find out more about how you can short Boston Scientific Corporation stock.

Boston Scientific Corporation's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Boston Scientific Corporation.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Boston Scientific Corporation's total ESG risk score

Total ESG risk: 29.23

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Boston Scientific Corporation's overall score of 29.23 (as at 12/31/2018) is nothing to write home about – landing it in it in the 57th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Boston Scientific Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Boston Scientific Corporation's environmental score

Environmental score: 1.51/100

Boston Scientific Corporation's social score

Social score: 12.87/100

Boston Scientific Corporation's governance score

Governance score: 7.87/100

Boston Scientific Corporation's controversy score

Controversy score: 3/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Boston Scientific Corporation scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Boston Scientific Corporation hasn't always managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Boston Scientific Corporation was last rated for ESG on: 2019-01-01.

Total ESG score 29.23
Total ESG percentile 56.94
Environmental score 1.51
Social score 12.87
Governance score 7.87
Level of controversy 3

Boston Scientific Corporation share dividends

We're not expecting Boston Scientific Corporation to pay a dividend over the next 12 months.

Have Boston Scientific Corporation's shares ever split?

Boston Scientific Corporation's shares were split on a 2:1 basis on 5 November 2003. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Boston Scientific Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Boston Scientific Corporation shares which in turn could have impacted Boston Scientific Corporation's share price.

Boston Scientific Corporation share price volatility

Over the last 12 months, Boston Scientific Corporation's shares have ranged in value from as little as US$32.99 up to US$46.29. A popular way to gauge a stock's volatility is its "beta".

BSX.US volatility(beta: 0.88)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Boston Scientific Corporation's is 0.8788. This would suggest that Boston Scientific Corporation's shares are less volatile than average (for this exchange).

Boston Scientific Corporation overview

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, and micro and drainage catheters to treat cancer. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site